데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
63610-09-3N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1.NC(CO)(CO)CO.NC(CO)(CO)CO63610-09-3CHEMBL3989725안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Lodoxamide tromethamine was launched as an ophthalmic formulation for the treatment of allergic conjunctivitis. It appears to act as a mast cell stabilizer inhibiting degranulation and the release of histamine and other vasoactive products in a similar manner to sodium cromoglycate. The compound is also under investigation as an orally active antiallergic/antiasthmatic agent.
용도cataract treatment
일반 설명Lodoxamidetromethamine, N, N -(2-chloro-5-cyano-m-phenylene)dioxamicacid (Alomide), is a white crystalline, water-solublepowder. The only significant structural similarity betweenlodoxamide and cromolyn and nedocromil is the presence oftwo acidic groups. Lodoxamide is indicated in the treatmentof the ocular disorders including vernal keratoconjunctivitis,vernal conjunctivitis, and vernal keratitis. Lodoxamide isavailable as a 0.1% solution, with each milliliter containing1.78 mg of lodoxamide tromethamine equivalent to 1 mg oflodoxamide. The solution contains the preservative benzalkoniumchloride (0.007%) as well as mannitol, hydroxypropylmethylcellulose, sodium citrate, citric acid, edetatedisodium, tyloxapol, hydrochloric acid and/or sodium hydroxide(to adjust pH), and purified water.The dose for adults and children older than 2 years of ageis 1 to 2 drops in each affected eye 4 times daily for up to 3months. The most frequently reported ocular adverse experienceswere transient burning, stinging, or discomfort oninstillation.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…